Considering the recurrent alteration of the PD-L1 gene in PCNSL and PTL and the poor prognosis of these rare subtypes of DLBCL [80], nivolumab was evaluated in patients with R/R PCNSL or R/R PTL, in whom it demonstrated impressive activity (NCT02857426), with clinical and radiographic response and PFS extended to 13+ to 17+ months for some patients [105]. Here, CD274 is linked to diffuse large B-cell lymphoma.